Maxwell Biotech and High-Tech Gr?nderfonds agree on cooperation

On April 4 at a joint press conference, two venture capital funds - the Russian Maxwell Biotech and the European High-Tech Gr?nderfonds (HTGF) - will sign a cooperation agreement, as well as talk about the prospects for a strategic partnership, under which they plan to implement joint projects in the biotechnology and pharmaceutical industries.

Dmitri Popov, the managing partner of a venture capital fund established with the participation of RVC OJSC capital, will represent Maxwell Biotech, and Bernd Gergen, the senior investment manager, will present High-Tech Gr?nderfonds.

Currently the first joint investment in the biotechnology project Gepatera / MYR on the development of innovative drug for the treating chronic viral hepatitis B and D has been allocated. In addition, the funds representatives will talk about the main activities of their funds, investment strategy and existing portfolio companies.

Yan Ryazantsev, the RVC OJSC investment director, and Alexander Lupachev, the Skolkovo investment fund director are invited to participate in this event; they will comment on expanding the Maxwell Biotech venture capital fund international partners network.

The address of the event is B.Yakimanka st., 1, Alexander House BC, the entrance is an orange door from B.Yakimanka street. The passport is required. Gathering and welcome coffee is from 13.00 to 13.30 near the conference room. The press conference takes place from 13.30 to 15.00.